In order to further the clinical development of BerGenBio’s lead candidate BGB324, to support the continued development of the Company’s preclinical pipeline, and for other purposes, BerGenBio undertook an initial public offering (“IPO”) of new shares in BerGenBio.

The first day of trading on Oslo Stock Exchange was April 7 2017.

The prospectus can be viewed here.